Search Clinical Trials
Thank you for your interest in Vanderbilt research! Taking part in research is one way to be part of tomorrow’s health care discoveries. Vanderbilt is always looking for volunteers just like you so that our researchers can better understand how to prevent, diagnose, and treat diseases. Everyone is needed. Both healthy volunteers and people with health conditions can help us answer important questions that impact the health of our communities. Ready to start searching for a study?
- Enter a health condition or leave it blank if you are looking to join any study as a healthy volunteer.
- Enter your gender and age.
- Click View Results.
- Click on the study titles for information.
- Click on Contact/Details tab to get information for contacting the study team.
Condition of Interest |
---|
GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab
Type 1 Diabetes
The goal of this study is to determine how a drug class called glucagon-like peptide-1
receptor agonists (GLP-1Ra) affects people during an early stage of Type 1 Diabetes
undergoing clinical teplizumab treatment. This study involves giving participants a
liquid meal under three different conditions... expand
The goal of this study is to determine how a drug class called glucagon-like peptide-1 receptor agonists (GLP-1Ra) affects people during an early stage of Type 1 Diabetes undergoing clinical teplizumab treatment. This study involves giving participants a liquid meal under three different conditions and observing how their bodies respond, focusing on blood sugar levels, insulin effectiveness, and blood vessel function. The first meal test is pre-teplizumab, followed by two post-treatment tests, one with the GLP-1Ra drug and the other with a placebo. Each test involves blood draws before and during the meal test, GLP-1Ra or placebo administration, and an ultrasound to measure blood vessel function. The goal is to see if GLP-1Ra can help manage blood sugar levels and improve cardiovascular health in this population. Type: Interventional Start Date: Jun 2024 |
Long COVID Immune Profiling
Long COVID
POTS - Postural Orthostatic Tachycardia Syndrome
Autonomic Dysfunction
Parasympathetic nervous system (PNS) is part of the body's autonomic nervous system(PNS)
protects body against inflammation. Study shows that reduced PNS function activity is
associated with persistent inflammation.
Preliminary data from the studies shows, that post-COVID-19 POTS patients have reduced
parasympathetic... expand
Parasympathetic nervous system (PNS) is part of the body's autonomic nervous system(PNS) protects body against inflammation. Study shows that reduced PNS function activity is associated with persistent inflammation. Preliminary data from the studies shows, that post-COVID-19 POTS patients have reduced parasympathetic (PNS) function. Given that the PNS protects against inflammation, this clinical trial aims to prove that post-COVID-19 POTS is caused by reduced PNS activity, which in turn, contributes to persistent inflammation, orthostatic intolerance, and OI symptoms. The study will evaluate immune cell activation in post-COVID-19 POTS and patients with history of COVID-19 infection without sequelae and correlate this with the degree of decreased PNS activity. Type: Interventional Start Date: Apr 2024 |
Metastatic Leiomyosarcoma Biomarker Protocol
Leiomyosarcoma
Leiomyosarcoma (LMS) is one of the most prevalent soft tissue sarcomas (STS) and can
occur in various sites including soft tissue, uterus and retroperitoneal large vessels.
Metastatic disease occurs in approximately 50% of patients diagnosed with leiomyosarcoma
and prognosis is poor in setting of... expand
Leiomyosarcoma (LMS) is one of the most prevalent soft tissue sarcomas (STS) and can occur in various sites including soft tissue, uterus and retroperitoneal large vessels. Metastatic disease occurs in approximately 50% of patients diagnosed with leiomyosarcoma and prognosis is poor in setting of metastatic disease. A minority of patients benefit from treatment with chemotherapy and early biomarkers of benefit from treatment are lacking. A biomarker of tumor response and patient survival benefit from chemotherapy early in the course of chemotherapy would be of significant impact in treatment planning. Circulating tumor DNA (ctDNA) is present in blood of patients with advanced/metastatic cancer and may serve as biomarker of tumor response to chemotherapy. Blood samples will be collected prior to and during and chemotherapy, and analyzed for ctDNA and for mutations in genes that are associated with increased risk of developing sarcoma. Tumor tissue will be collected and analyzed for changes in genes. Digital images of the sarcoma from CT or MRI scans obtained during treatment will be obtained for advanced radiomic analysis. Study participants will be asked to complete a questionnaire on attitudes and understanding of genetics and genetic testing. Type: Observational Start Date: Dec 2022 |
Effect of Donepezil on Speech Recognition in Cochlear Implant Users
Bilateral Sensorineural Hearing Loss
Hearing loss is a major cause of disability that affects over 48 million Americans. There
are currently no medications used to treat sensorineural hearing loss. Cochlear implants
can significantly restore hearing in adults with moderate to profound sensorineural
hearing loss, but their utility is... expand
Hearing loss is a major cause of disability that affects over 48 million Americans. There are currently no medications used to treat sensorineural hearing loss. Cochlear implants can significantly restore hearing in adults with moderate to profound sensorineural hearing loss, but their utility is limited by the wide variability in hearing outcomes. Differences in cochlear implant outcomes may be explained by neuroplasticity, as neural networks must reorganize to process the new auditory information provided by the implant. The investigators predict that cholinergic enhancement with donepezil (an acetylcholinesterase inhibitor) may facilitate cortical reorganization in cochlear implant users, leading to functional improvements in speech recognition and cognition. In addition to taking donepezil, study participants will be asked to increase their daily processor use. Studies suggest that increasing daily device use can improve speech recognition, and this study will explore whether this effect can be augmented further with donepezil. In this randomized, double-blind controlled trial, the investigators aim to assess the effects of donepezil on speech recognition, cortical plasticity, and cognition. Participants will start daily treatment with either donepezil 5 mg or placebo. Participants will be followed longitudinally at 1 month and 3 months after starting the study. The findings from this study will provide important insight into the mechanisms of hearing restoration and could potentially improve hearing and cognitive outcomes for future cochlear implant users. Type: Interventional Start Date: Mar 2023 |
RESPONDER-HF Trial
Heart Failure
Heart Failure, Diastolic
Multicenter, Prospective, Randomized, Sham Controlled, Double Blinded Clinical Trial,
with; 1:1 randomization expand
Multicenter, Prospective, Randomized, Sham Controlled, Double Blinded Clinical Trial, with; 1:1 randomization Type: Interventional Start Date: Nov 2022 |
A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Type 2 Diabetes Mellitus
Chronic Kidney Diseases
The purpose of this study is to assess the safety and efficacy (including durability) of
up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously
into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD. expand
The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD. Type: Interventional Start Date: Jan 2022 |
Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma
Metastatic Melanoma
BRAF Gene Mutation
This is a phase 1 dose-escalation study of nilotinib in combination with fixed-dose
dabrafenib and trametinib regimen for patients with metastatic or unresectable melanoma
carrying a BRAF V600 mutation and have relapsed on a BRAF/MEK inhibitor therapy. The goal
is to assess the toxicity and tolerability... expand
This is a phase 1 dose-escalation study of nilotinib in combination with fixed-dose dabrafenib and trametinib regimen for patients with metastatic or unresectable melanoma carrying a BRAF V600 mutation and have relapsed on a BRAF/MEK inhibitor therapy. The goal is to assess the toxicity and tolerability and determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of the combination of nilotinib with dabrafenib and trametinib. Additionally, this study will assess pharmacokinetic parameters of dabrafenib and nilotinib when used in combination. Type: Interventional Start Date: Jun 2022 |
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic...
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
This phase III trial compares early treatment with venetoclax and obinutuzumab versus
delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed
high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a
class of medications called B-cell lymphoma-2... expand
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with the venetoclax and obinutuzumab early (before patients have symptoms) may have better outcomes for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared to starting treatment with the venetoclax and obinutuzumab after patients show symptoms. Type: Interventional Start Date: Mar 2021 |
Liberation From Acute Dialysis
Acute Kidney Injury
Kidney; Disease, Acute
Dialysis Related Complication
The goal of the LIBERATE-D clinical trial is to improve outcomes for patients recovering
from dialysis-requiring acute kidney injury (AKI-D). The impact of a conservative
dialysis strategy compared to standard clinical practice of thrice-weekly dialysis will
be examined to help generate knowledge... expand
The goal of the LIBERATE-D clinical trial is to improve outcomes for patients recovering from dialysis-requiring acute kidney injury (AKI-D). The impact of a conservative dialysis strategy compared to standard clinical practice of thrice-weekly dialysis will be examined to help generate knowledge for how to guide delivery of dialysis to facilitate renal recovery. Type: Interventional Start Date: Jan 2020 |
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
Hydrocephalus
Hydrocephalus is a potentially debilitating neurological condition that primarily affects
babies under a year of age and has traditionally been treated by inserting a shunt
between the brain and the abdomen. A newer endoscopic procedure offers hope of shunt-
free treatment that may reduce complications... expand
Hydrocephalus is a potentially debilitating neurological condition that primarily affects babies under a year of age and has traditionally been treated by inserting a shunt between the brain and the abdomen. A newer endoscopic procedure offers hope of shunt- free treatment that may reduce complications over a child's life, but it is not clear if the endoscopic procedure results in similar intellectual outcome as shunt. Therefore, the investigators propose a randomized trial to compare intellectual outcome and brain structural integrity between these two treatments, to help families make the best treatment decision for their baby. Type: Interventional Start Date: Jul 2020 |
Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
Breast Screening
This randomized phase III trial studies digital tomosynthesis mammography and digital
mammography in screening patients for breast cancer. Screening for breast cancer with
tomosynthesis mammography may be superior to digital mammography for breast cancer
screening and may help reduce the need for... expand
This randomized phase III trial studies digital tomosynthesis mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment. Type: Interventional Start Date: Sep 2017 |
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Hematologic Malignancies
Inherited Disorders of Metabolism
Inherited Abnormalities of Platelets
Histiocytic Disorders
Acute Myelogenous Leukemia (AML or ANLL)
This study is an access and distribution protocol for unlicensed cryopreserved cord blood
units (CBUs) in pediatric and adult patients with hematologic malignancies and other
indications. expand
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications. Type: Observational Start Date: Oct 2011 |
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
Cholangiocarcinoma
This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate
the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with
Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR
Inhibitor-Refractory/Relapsed Cholangiocarcinoma expand
This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma Type: Interventional Start Date: Dec 2023 |
Abbott Ventricular Tachycardia PAS
Ventricular Tachycardia
This post-approval study (PAS) is designed to provide continued clinical evidence to
confirm the long-term safety and effectiveness of the FlexAbilityTM Ablation Catheter,
Sensor EnabledTM (FlexAbility SE) for the treatment of ventricular tachycardia in a
post-market environment. This is a prospective,... expand
This post-approval study (PAS) is designed to provide continued clinical evidence to confirm the long-term safety and effectiveness of the FlexAbilityTM Ablation Catheter, Sensor EnabledTM (FlexAbility SE) for the treatment of ventricular tachycardia in a post-market environment. This is a prospective, single arm, open-label, multi-center, observational study. Type: Observational Start Date: Jul 2023 |
Treating Exacerbations of Asthma With Oral Montelukast in Children
Status Asthmaticus
This research will establish a mg/kg dose for a future RCT to determine the efficacy of
high-dose oral montelukast for children with moderate and severe acute asthma
exacerbations.
Aim: Perform an adaptive, double-masked randomized controlled trial (RCT) of high-dose
oral montelukast, with escalating... expand
This research will establish a mg/kg dose for a future RCT to determine the efficacy of high-dose oral montelukast for children with moderate and severe acute asthma exacerbations. Aim: Perform an adaptive, double-masked randomized controlled trial (RCT) of high-dose oral montelukast, with escalating mg/kg dose levels determined by PK-guided dose modeling, added to standard treatment versus standard treatment alone, in children with exacerbations that are moderate or severe after initial treatment with inhaled albuterol. Hypothesis 1: High-dose oral montelukast achieves peak plasma concentration (Cmax) >1,700 ng/ml in >86% of at least one of three sequential participant groups with escalating weight-based (milligram/kilogram or mg/kg) doses between groups. Hypothesis 2: Participants randomized to high-dose oral montelukast have a 2 point or greater improvement of the validated Acute Asthma Intensity Research Score (AAIRS) at 4 hours post-treatment in comparison with control group participants. Hypothesis 3: Among montelukast recipients, Cmax correlates with change of the AAIRS at 4 hours, after adjustment for pre-treatment exacerbation severity and systemic leukotriene stress measured using urinary leukotriene E4 (LTE4). Type: Interventional Start Date: Oct 2023 |
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine)...
Metastatic Colorectal Carcinoma
Metastatic Malignant Solid Neoplasm
Stage IV Colorectal Cancer AJCC v8
Unresectable Colorectal Carcinoma
Unresectable Malignant Solid Neoplasm
This phase I trial tests the safety, side effects, and best dose of ZEN003694 in
combination with the usual treatment with capecitabine in treating patients with cancer
that has spread from where it first started (primary site) to other places in the body
(metastatic) or cannot be removed by surgery... expand
This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with the usual treatment with capecitabine in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable) and that it has progressed on previous standard treatment. ZEN003694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that over produce BET protein. Capecitabine is in a class of medications called antimetabolites. It is taken up by cancer cells and breaks down into fluorouracil, a substance that kills cancer cells. Giving ZEN003694 in combination with capecitabine may be safe in treating patients with metastatic or unresectable solid tumors. Type: Interventional Start Date: Nov 2023 |
Cryoablation for Monomorphic Ventricular Tachycardia
Sustained VT
The objective of this clinical study is to evaluate the safety and effectiveness of the
Adagio VT Cryoablation System in the ablation treatment of Sustained Monomorphic
Ventricular Tachycardia (SMVT) expand
The objective of this clinical study is to evaluate the safety and effectiveness of the Adagio VT Cryoablation System in the ablation treatment of Sustained Monomorphic Ventricular Tachycardia (SMVT) Type: Interventional Start Date: Sep 2023 |
A Study to Investigate the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder
CDKL5 Deficiency Disorder
Generalized Tonic Clonic Seizure
Epileptic Spasm
Refractory Seizures
This is a multicenter, double-blind, parallel-group, placebo controlled, 2-part study to
evaluate the efficacy and safety of ZX008 when used as adjunctive therapy for the
treatment of uncontrolled seizures in children and adults with cyclin-dependent kinase
like-5 (CDKL5) deficiency disorder (CDD). expand
This is a multicenter, double-blind, parallel-group, placebo controlled, 2-part study to evaluate the efficacy and safety of ZX008 when used as adjunctive therapy for the treatment of uncontrolled seizures in children and adults with cyclin-dependent kinase like-5 (CDKL5) deficiency disorder (CDD). Type: Interventional Start Date: Mar 2022 |
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
Lung Cancer
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory
may help doctors learn more about changes that may occur in RNA and identify biomarkers
related to cancer.
PURPOSE: This research study is collecting and analyzing lung tissue samples from
patients undergoing... expand
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that may occur in RNA and identify biomarkers related to cancer. PURPOSE: This research study is collecting and analyzing lung tissue samples from patients undergoing surgery for non-small cell lung cancer. Type: Observational Start Date: May 2001 |
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
Advanced or Metastatic Solid Tumors
The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101
alone or in combination with pembrolizumab in adults with advance or metastatic solid
tumors. expand
The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors. Type: Interventional Start Date: Mar 2023 |
Genetics of Appendix Cancer Study
Appendix Cancer
Appendiceal Cancer
Appendiceal Neoplasms
Appendiceal Mucinous Neoplasm
Appendiceal Adenocarcinoma
The GAP Study is a prospective cohort study designed to comprehensively investigate
genetic variations that may contribute to cancer development among individuals diagnosed
with appendix/appendiceal cancer who are ages 18+ years. expand
The GAP Study is a prospective cohort study designed to comprehensively investigate genetic variations that may contribute to cancer development among individuals diagnosed with appendix/appendiceal cancer who are ages 18+ years. Type: Observational Start Date: Nov 2022 |
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma
Metastatic Breast Cancer
This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate
the impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with
non-Luminal A hormone receptor-positive (HR+) metastatic breast cancer (MBC) expand
This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with non-Luminal A hormone receptor-positive (HR+) metastatic breast cancer (MBC) Type: Interventional Start Date: Sep 2023 |
Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas
Liposarcoma, Dedifferentiated
Study SPH4336-US-01 is an open-label (no placebo), multicenter clinical trial to evaluate
the safety, blood levels (pharmacokinetics) and preliminary anti-tumor effects of
SPH4336, a selective enzyme blocker, in patients with specific types of liposarcomas
(tumors expressing the target of the study... expand
Study SPH4336-US-01 is an open-label (no placebo), multicenter clinical trial to evaluate the safety, blood levels (pharmacokinetics) and preliminary anti-tumor effects of SPH4336, a selective enzyme blocker, in patients with specific types of liposarcomas (tumors expressing the target of the study drug). Type: Interventional Start Date: Aug 2023 |
Cryospray Therapy Versus Standard of Care for Benign Airway Stenosis (CryoStasis)
Pulmonary Disease
Benign central airway stenosis (BCAS) is an important cause of both pulmonary morbidity
and mortality. Notable causes include post-intubation stenosis, collagen vascular
diseases, airway trauma, infectious and idiopathic subglottic stenosis (iSGS). Surgery is
the preferred definite option; however,... expand
Benign central airway stenosis (BCAS) is an important cause of both pulmonary morbidity and mortality. Notable causes include post-intubation stenosis, collagen vascular diseases, airway trauma, infectious and idiopathic subglottic stenosis (iSGS). Surgery is the preferred definite option; however, the first therapeutic attempt is usually endoscopic to temporarily restore airway patency and symptomatic improvement. Several endoscopic modalities exist for treatment. Most commonly, thermal or laser therapy to make radial incisions into the stenotic lesion, followed by balloon dilation to increase the area of patency. Clinicians may also inject steroids or antineoplastic agents such as mitomycin C. All of these methods have benefits and associated risks. Symptomatic stenosis frequently reoccurs with these methods. For example, the investigators have been doing 3-4 ballon dilations procedures a week at our institution. Spray cryotherapy (SCT) is a novel FDA-cleared technique that allows for liquid nitrogen to be delivered through the working channel of a bronchoscope. Few retrospective studies exist without more robust clinical trial data to reduce the risk of bias and support its widespread use. The investigators postulate that SCT and standard of care techniques will improve airway patency volume at six months than the standard of care techniques alone. Some of the proposed advantages include improved wound healing which may translate to less scar tissue and thus improvements in airway patency for a longer duration of time. Type: Interventional Start Date: Oct 2021 |
Competency Based Approaches for Community Health 2
Obesity
One-size-fits-all approaches have failed to demonstrate sustained effects on childhood
obesity, especially among low-income minority families, who experience constantly
changing barriers to engaging in health behavior. Addressing obesity in these populations
requires intervening in early childhood... expand
One-size-fits-all approaches have failed to demonstrate sustained effects on childhood obesity, especially among low-income minority families, who experience constantly changing barriers to engaging in health behavior. Addressing obesity in these populations requires intervening in early childhood and situating interventions in the context of families and communities. Developing personalized childhood obesity prevention interventions with sustained effectiveness that support families in health behaviors despite dynamic barriers could address chronic disease risk and health disparities in low-income and minority communities. Type: Interventional Start Date: Nov 2021 |
- Previous
- Next